T Lymphocyte Activation Markers as Predictors of Responsiveness to Rituximab among Patients with FSGS

Featured Image

Why is it important?

We have identified prognostic markers which could help in selecting a subgroup of FSGS patients who may better respond to rituximab. The other side of the coin is that identifying patients who will not respond to rituximab could therefore prevent patients from unjustifiably exposed to the costs and risks of the treatment.